Sunshine Lake Pharma Co., Ltd.

Shanghai Micro Electronics Equipment (group) Co., Ltd.

Ruyuan Hec Pharm Co., Ltd.

Shanghai Micro Electronics Equipment Co., Ltd.

Shanghai Sundise Chinese Medicine Technology Development Co., Ltd

Shanghai Sundise

Ma, Yueming

Zhang, Yongyu

Wang, Tianming

Tianming Wang

Feibiao Chen

Hai Xia

Xin Lei

Yueming Ma

Yongyu Zhang

Zhiqing Lv

Siegfried Goldmann

Yingjun Zhang

Qingyun Ren

Xinchang Liu

Yuebin Zhu

Xiaoyu Jiang

Song Guo

Jianqi Sun

Chaolei Wang

Jinan Peng

Wan Li

A chip bonding apparatus and method are disclosed. The chip bonding apparatus includes: at least one separation module for separating chips; at least one bonding module for bonding the chips a substrate; a transportation device for transporting the chips between the separation module and the bonding module, the transportation device including one or more guide tracks and one or more transportation carriers for retaining the chips, each of the guide tracks is provided thereon with at least one of the transportation carriers; and a control device for individually controlling the separation module, the bonding module and the transportation device. The chip bonding apparatus and method allows pickup, transportation and chip-to-substrate bonding of chips in batches with increased chip bonding yield and improved chip bonding accuracy.

Chip bonding device and bonding method thereof

Provided are a chip bonding apparatus and bonding method. The apparatus comprises: a chip supply unit (); a substrate supply unit (); a first pick-up assembly () arranged between the chip supply unit () and the substrate supply unit (), comprising a first rotating component and a first pick-up head arranged on the first rotating component; a second pick-up assembly () comprising a second rotating component and a second pick-up head arranged on the second rotating component, wherein the first pick-up assembly () picks up a chip () from the chip supply unit () or the second pick-up assembly (), and delivers the chip () onto a substrate of the substrate supply unit () to complete the bonding; and a vision unit () for realizing the alignment of the chip () and the substrate on the first pick-up assembly (), wherein the chip supply unit (), the substrate supply unit (), the second pick-up assembly () and the vision unit () are respectively located on four work positions of the first pick-up head. The chip () is transported through rotation, improving the productivity of chip () bonding; and the chip () is reversed by utilizing the second pick-up assembly (), which is compatible with two ways of bonding, i.e. a mark face of the chip () facing upwards and downwards.

Chip bonding apparatus and bonding method

A balance mass system shared by a workpiece stage and a mask stage includes a balance mass and an anti-drift and compensation apparatus (). The balance mass includes a first part () for mounting thereon a workpiece stage system, a second part () for mounting thereon a mask stage system, and a third part () for interconnecting the first part () and the second part (). The first part () of the balance mass is floatingly supported on a base frame () of a lithography machine, and the third part () of the balance mass is in connection with the base frame () via the anti-drift and compensation apparatus (). The anti-drift and compensation apparatus () is disposed in proximity to the center of gravity of the balance mass as a whole. This balance mass system can eliminate the need for using an additional support for the mask stage system and allow the construction of a lithography machine with a higher structural compactness, reduced size and weight, and reduced total mass of used balance masses.

Balance mass system shared by workpiece table and mask table, and lithography machine

The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L. The substantially pure crystalline forms of azilsartan medoxomil potassium of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.

Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof

The present invention relates to crystalline forms of dihydropyrimidine derivatives, and pharmaceutical compositions comprising the crystalline forms disclosed herein, which may be used for preventing, managing, treating or lessening the severity of a viral disease in a patient, especially hepatitis B infection or a disease caused by hepatitis B infection.

Crystalline forms of dihydropyrimidine derivatives

The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.

Crystalline forms of azilsartan and preparation and uses thereof

The present invention relates to a determination method of a blood plasma amygdalin of body resistance-strengthening and blood stasis-dissipating botanical composition, comprising the following steps: (1) first adding 2-5 mol/L phosphoric acid to the plasma of mammals administered with the blood stasis-dissipating botanical composition, and mixing to homogenize, the volumetric ratio of plasma to phosphoric acid is 1:2-3, applying the solution to a small column of Waters Oasis HLB activated by methanol and water, after leaching by water and 80-100% methanol and eluting by 0.2-1% ammonia-methanol, drying through evaporation and enriching the eluent at 25-30&#xb0; C.; and re-dissolving with a mobile phase; (2) UPLC/MS determination method: chromatographic conditions: chromatographic column: Acquity UPLC BEH C, 2.1&#xd7;100 mm, mobile phase A: Water-Acetonitrile-Formic acid 95:5:0.1 v/v/v, mobile phase B: Acetomtrile-Formic acid 100:0.1 v/v; MS conditions: electrospray ionization (ESI) ion source, detection in the positive ion mode, and the mass scanning range m/z 150&#x2dc;800. The present invention can be used for pharmacokinetic studies of amygdalin of body resistance-strengthening and blood stasis-dissipating botanical composition.

Detection of blood plasma amygdalin of dissipating blood stasis botanical

A detection method of blood plasma danshensu and salvianolic acid B of dissipating blood stasis botanical is disclosed. The method includes: (1) pretreating mammalian plasma sample: applying the plasma with medicine to small column of Waters Oasis HLB activated by methanol and water; after leaching and eluting, drying and enriching the eluent; after redissolving with mobile phase, measuring by UPLC/MS; (2) UPLC/MS measuring: UPLC condition: chromatographic column: Acquity UPLC BEH C, 2.1'100 mm, mobile phase A: water-acetonitrile-formic acid 95:5:0.1 v/v/v, mobile phase B: acetonitrile-formic acid 100:0.1 v/v; MS condition: electric spraying ion source (ESI), detecting with negative ion mode, scanning at the range of m/z 150-800. The method can be used for pharmacokinetics study of danshensu and salvianolic acid B in dissipating blood stasis botanical.

Detection of blood plasma Danshensu and Salvianolic acid B dissipating blood stasis botanical

Growing community of inventors

Shanghai, China

Tianming Wang